Isopropamide iodide
From Wikipedia, the free encyclopedia
| Image:Isopropamide iodide.png | |
|
Isopropamide iodide
|
|
| Systematic (IUPAC) name | |
| (3-carbamoyl-3,3-diphenyl-propyl)-methyl-dipropan-2-yl-azanium iodide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C23H33IN2O |
| Mol. mass | 480.43 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. Isopropamide iodide is administered orally. It was discovered at Janssen Pharmaceutica in 1954.
[edit] References
- Seeherman R, Isopropamide iodide: a long-acting anticholinergic, Del Med J. 1957 Oct;29(10):265-9.
- Boss EG Jr, Buchanan GC, Effect of isopropamide iodide on basal gastric secretion in the human, Gastroenterology. 1957 Nov;33(5):730-6.
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
